<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<!--The publisher of this article does not allow downloading of the full text in XML form.-->
<?properties manuscript?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-journal-id">9602487</journal-id>
<journal-id journal-id-type="pubmed-jr-id">21197</journal-id>
<journal-id journal-id-type="nlm-ta">Curr Pharm Des</journal-id>
<journal-id journal-id-type="iso-abbrev">Curr. Pharm. Des.</journal-id>
<journal-title-group>
<journal-title>Current pharmaceutical design</journal-title>
</journal-title-group>
<issn pub-type="ppub">1381-6128</issn>
<issn pub-type="epub">1873-4286</issn>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">31742491</article-id>
<article-id pub-id-type="pmc">7100710</article-id>
<article-id pub-id-type="doi">10.2174/1381612825666191119093335</article-id>
<article-id pub-id-type="manuscript">ASMS1559781</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Prenatal stress and maternal immune dysregulation in autism spectrum disorders- potential points for intervention</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Beversdorf</surname>
<given-names>David Q.</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
<xref ref-type="corresp" rid="CR1">*</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Stevens</surname>
<given-names>Hanna E.</given-names>
</name>
<xref ref-type="aff" rid="A2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Margolis</surname>
<given-names>Kara Gross</given-names>
</name>
<xref ref-type="aff" rid="A3">3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Van de Water</surname>
<given-names>Judy</given-names>
</name>
<xref ref-type="aff" rid="A4">4</xref>
</contrib>
</contrib-group>
<aff id="A1"><label>1.</label>Departments of Radiology, Neurology, and Psychological Sciences, and The Thompson Center for Neurodevelopmental Disorders, University of Missouri, William and Nancy Thompson Endowed Chair in Radiology.</aff>
<aff id="A2"><label>2.</label>Departments of Psychiatry and Pediatrics, Iowa Neuroscience Institute, University of Iowa.</aff>
<aff id="A3"><label>3.</label>Department of Pediatrics, Division of Pediatric Gastroenterology, Hepatology and Nutrition, Morgan Stanley Childrenâ€™s Hospital, Columbia University Medical Center.</aff>
<aff id="A4"><label>4.</label>Department of Internal Medicine, Division of Rheumatology, Allergy, and Clinical Immunology, And the MIND Institute, University of California, Davis.</aff>
<author-notes>
<corresp id="CR1"><label>*</label>Address correspondence to this author at DC069.10, Department of Radiology, University of Missouri, One Hospital Drive, Columbia, MO 65212; 573-882-6081; <email>beversdorfd@health.missouri.edu</email></corresp>
<fn fn-type="COI-statement" id="FN1">
<p id="P33">CONFLICTS OF INTEREST</p>
<p id="P34">Dr. Beversdorf serves in an advisory capacity for Yamo Pharmaceuticals, Quadrant Biosciences, and Stalicla, unrelated to this work. Drs Stevens, Margolis, and Van de Water have nothing to disclose.</p>
</fn>
</author-notes>
<pub-date pub-type="nihms-submitted">
<day>23</day>
<month>2</month>
<year>2020</year>
</pub-date>
<pub-date pub-type="ppub">
<year>2019</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>27</day>
<month>3</month>
<year>2020</year>
</pub-date>
<volume>25</volume>
<issue>41</issue>
<fpage>4331</fpage>
<lpage>4343</lpage>
<!--elocation-id from pubmed: 10.2174/1381612825666191119093335-->
<abstract id="ABS1">
<p id="P1">Genetics are a major etiological contributor to autism spectrum disorder (ASD). Environmental factors, however, also appear to contribute. ASD pathophysiology due to gene x environment is also beginning to be explored. One reason to focus on environmental factors is that they may allow opportunities for intervention or prevention. Two such factors that have been associated with a significant proportion of ASD risk are prenatal stress exposure and maternal immune dysregulation. Maternal stress susceptibility appears to interact with prenatal stress exposure to affect offspring neurodevelopment. Additionally, understanding of the impact of maternal immune dysfunction on ASD has recently been advanced by recognition of specific fetal brain proteins targeted by maternal autoantibodies, and identification of unique mid-gestational maternal immune profiles. Animal models have been developed to explore pathophysiology targeting both of these factors. We are beginning to understand the behavioral, pharmacopathological, and epigenetic effects related to these interactions, as well as potential mitigating factors. Continued growth in understanding of these mechanisms may ultimately allow for the identification of multiple potential points for prevention or intervention for this subset of environmental-associated ASD cases.</p>
</abstract>
<kwd-group>
<kwd>Autism spectrum disorder</kwd>
<kwd>prenatal stress</kwd>
<kwd>immune dysregulation</kwd>
<kwd>maternal antibodies</kwd>
<kwd>microbiome</kwd>
</kwd-group>
</article-meta>
</front>
</article>
</pmc-articleset>